Latest news with #MetforminHydrochloride
Time of India
25-06-2025
- Business
- Time of India
Haffkine to quiz 2 pharmaceutical firms for selling it ‘blacklisted' medicines for government hospitals in Maharashtra
Mumbai: Haffkine Bio-Pharmaceuticals procurement cell will be seeking explanations from two pharmaceutical firms after it came to light that medicines ordered for govt hospitals across the state in Feb had been declared "not of standard quality" and blacklisted by Employees' State Insurance Corporation (ESIC) just two months earlier. In Dec, ESIC issued a circular blacklisting specific drugs from seven pharmaceutical companies, citing test results that found these medicines to be of substandard quality and directing that no further orders be placed with them. However, Haffkine Bio-Pharmaceuticals placed large supply orders with two of the listed firms. This resulted in the procurement of nearly 21.9 lakh vials of Pantoprazole 40mg/10ml injection worth Rs 2.5 crore from Galpha Laboratories Ltd, and 88,650 tablets of Vildagliptin 50mg, along with Metformin Hydrochloride 1000mg worth nearly Rs 12.6 lakh, from Bajaj Healthcare Ltd. Pantoprazole is used to treat acid-related stomach issues such as ulcers and acid reflux, while Vildagliptin with Metformin is prescribed to manage type 2 diabetes by controlling blood sugar levels. Although Haffkine is no longer the primary authority for medicine procurement, it was granted permission to utilise the remaining Rs 131.6 crore to restock medicines at state-run hospitals through a Govt Resolution (GR). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar "The procurement process must be based on ESIC rate contracts as received on the e-Aushadhi platform," the GR stated. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai A senior official at the procurement cell confirmed that they are looking into the matter. "We have been orally informed by ESIC that the issue pertained to specific batches. Nevertheless, we have sought written responses from the companies as well as from ESIC. These will be submitted to higher authorities, and payments to the companies will be withheld until a reasonable explanation is provided," the official said, but did not provide the amount of payments to be withheld. Abhay Pandey, of the All Food and Drug Licence Holders Foundation, who flagged the issue with medical education department officials, alleged that the existing rate contract was arbitrarily selected by Haffkine without verifying the blacklisting status of the companies or conducting additional tests on the medicines. Haffkine officials did not respond when asked whether random sampling of the procured products was conducted in accordance with the GR. Dr Shashi Kolnoorkar, state ESIC director (Medical), said the blacklisting order came from the Delhi headquarters and that appropriate action had been taken at the time. When asked whether the blacklisting applied to specific batches or constituted a complete ban on the medicines in question, he referred the query to the ESIC head office. Attempts were made to reach Dr Neeta Garbiyal, deputy medical commissioner at the ESIC head office, who had signed the blacklist circular, but she was unavailable for comment. File pic
GMA Network
09-06-2025
- Health
- GMA Network
10 more meds for diabetes, cancer, other illnesses added to VAT-free list
The Food and Drug Administration (FDA) has added more medicines for cancer, diabetes, high cholesterol, hypertension, and mental illness in its list of drugs exempted from value-added tax (VAT). Under FDA Advisory No. 2025-0510 dated June 4, the FDA included two medicines for cancer, two for diabetes, one for high cholesterol, two for hypertension, and three for mental illness. For cancer, the medicines included in the VAT exemption are: Tegafur + Gimeracil + Oteracil Potassium capsule (20 mg/5.8 mg/19.6 mg) Tegafur + Gimeracil + Oteracil Potassium capsule (25 mg/7.25 mg/24.5 mg) For diabetes, the following medicines are exempted: Metformin Hydrochloride + Teneligliptin extended-release tablet (as hydrobromide hydrate) (1 g/20 mg) Metformin Hydrochloride + Teneligliptin extended release tablet (as hydrobromide hydrate) (500 mg/20 mg) The following is included for high cholesterol: Atorvastatin (as calcium) + Fenobribrate film-coated tablet (20 mg/160 mg) For hypertension, the following medicines are included: Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (50 mg/5 mg) Metoprolol tartrate + Ivabradine film-coated tablet (as hydrochloride) (25 mg/5 mg) Meanwhile, the following are the medicines included for mental illnesses: Lamotrigine dispersible/chewable tablet (5 mg) Lamotrigine oral dispersible tablet (25 mg) Lamotrigine tablet (25 mg) Meanwhile, the FDA removed the medicine Baricitinib (2 mg and 4 mg) for cancer from the list. —Joahna Lei Casilao/AOL, GMA Integrated News
Business Standard
30-05-2025
- Business
- Business Standard
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
Marksans Pharma said that its UK-based wholly owned subsidiary Relonchem has received marketing authorization for Metformin Hydrochloride oral solution product from UK Medicines & Healthcare Products Regulatory Agency. Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE.
Business Upturn
30-05-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
07-05-2025
- Business
- Business Standard
Trimax Biosciences achieves EDQM Certificate of Suitability for Metformin Hydrochloride
Sigachi Industries announced that Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for Metformin Hydrochloride from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets, further strengthening Sigachi's presence in highly regulated pharmaceutical markets. Powered by Capital Market - Live News
